- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00843193
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
November 13, 2017 updated by: GlaxoSmithKline
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma
Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A Multi-Centre, Multi-country, Randomized, Double-Blind (Subject, Investigator), Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma
Study Type
Interventional
Enrollment (Actual)
198
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lille, France, 59037 cedex
- GSK Investigational Site
-
Marseille, France, 13009
- GSK Investigational Site
-
Montpellier, France, 34295
- GSK Investigational Site
-
Nantes, France, 44093
- GSK Investigational Site
-
Saint Pierre Cedex, France, 97448
- GSK Investigational Site
-
Strasbourg, France, 67091
- GSK Investigational Site
-
Tarbes Cedex 09, France, 65013
- GSK Investigational Site
-
-
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60596
- GSK Investigational Site
-
Gelnhausen, Hessen, Germany, 63571
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Germany, 39112
- GSK Investigational Site
-
-
-
-
-
Eindhoven, Netherlands, 5623 EJ
- GSK Investigational Site
-
Heerlen, Netherlands, 6419 PC
- GSK Investigational Site
-
Hoorn, Netherlands, 1624 NP
- GSK Investigational Site
-
-
-
-
-
Elverum, Norway, 2408
- GSK Investigational Site
-
Trondheim, Norway, 7006
- GSK Investigational Site
-
-
-
-
-
Bialystok, Poland, 15-276
- GSK Investigational Site
-
Gidle, Poland, 97-540
- GSK Investigational Site
-
Krakow, Poland, 31-023
- GSK Investigational Site
-
Lodz, Poland, 90-153
- GSK Investigational Site
-
Warszawa, Poland, 02-097
- GSK Investigational Site
-
-
-
-
-
Bellville, South Africa, 7530
- GSK Investigational Site
-
Bloemfontein, South Africa, 9301
- GSK Investigational Site
-
Mowbray, South Africa, 7700
- GSK Investigational Site
-
-
Gauteng
-
Cape Town, Gauteng, South Africa, 7505
- GSK Investigational Site
-
-
-
-
-
Belfast, United Kingdom, BT9 7AB
- GSK Investigational Site
-
London, United Kingdom, SE1 1YR
- GSK Investigational Site
-
Nottingham, United Kingdom, NG5 1PB
- GSK Investigational Site
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 6YD
- GSK Investigational Site
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XP
- GSK Investigational Site
-
-
-
-
Oregon
-
Medford, Oregon, United States, 97504
- GSK Investigational Site
-
Portland, Oregon, United States, 97213
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburg, Pennsylvania, United States, PA 15213
- GSK Investigational Site
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- GSK Investigational Site
-
-
Texas
-
Boerne, Texas, United States, 78006
- GSK Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- history of asthma for ≥ 6 months
- taking inhaled corticosteroids
- non-smoking
- Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.
- Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol.
- symptomatic according to the ACQ-7
Exclusion Criteria:
- Unstable severe asthma
- Recent respiratory illness
- Presence of other respiratory disease or chronic pulmonary condition other than asthma
- Treatment with omalizumab within 4 months of study
- Recent gastrointestinal or respiratory parasitic infestation
- History of severe allergy to food or drugs
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GSK679586
Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
|
GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour.
The infusion will be delivered by a programmable infusion pump
Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study.
Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
|
Placebo Comparator: PLACEBO
Subjects will receive three, once monthly intravenous administration of saline, according to randomization
|
Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study.
Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour.
The infusion will be delivered by a programmable infusion pump
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Asthma Control Questionnaire (ACQ-7) Over 12 Weeks
Time Frame: Baseline to Week 12
|
The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation).
The values of Week 1 is considered as Baseline.
ACQ-7 was calculated as the average of the 7 scores.
If any one individual score was missing, the ACQ-7 was set to missing.The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing as well.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in ACQ-7 Over 16 Weeks and 24 Weeks
Time Frame: Week 16 and Week 24
|
The ACQ-7 is a 7-item questionnaire that provides a measure of a participant's asthma control.
Participant responses were recorded on a 7-point scale ranging from zero (no impairment/ limitation) to 6 (total impairment/ limitation).
The values of Week 1 is considered as Baseline.
The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing as well.
Change from Baseline of Week 16 and Week 24 are incorporated here which are Follow up weeks.
|
Week 16 and Week 24
|
Number of Participants Who Demonstrated a Clinically Meaningful Change in ACQ-7 Over the 12 Weeks Assessment Period.
Time Frame: Upto 12 weeks
|
The ACQ-7 is a 7-item questionnaire that provides a measure of a participant's asthma control.
Participant responses were recorded on a 7-point scale ranging from zero (no impairment/ limitation) to 6 (total impairment/ limitation).
The percentage of participants who were classified as responders for ACQ-7, defined as a clinically meaningful decrease from baseline in ACQ-7 of at least 0.50, was generally similar between treatment groups at each visit and over the 12-week treatment period.
|
Upto 12 weeks
|
Change From Baseline in Forced Expiratory Volume (FEV1) Over 12 Weeks.
Time Frame: Baseline to Week 12
|
FEV1 is forced expiratory volume in 1 second.Change from Baseline FEV1 was calculated for each of the following visit: Visit 6, Visit 7, Visit 9 and Visit 11.
A binary variable was created for each participant with 1 for the responder and 0 for the non nonresponder at each visit.
Week 1 was considered as the Baseline.
The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing as well.
|
Baseline to Week 12
|
Change From Baseline in FEV1 Over 16 Weeks and 24 Weeks
Time Frame: Week 16 and 24
|
FEV1 is forced expiratory volume in 1 second.Change from Baseline FEV1 was calculated for each of the following visit: Visit 6, Visit 7, Visit 9 and Visit 11.
A binary variable was created for each participant with 1 for the responder and 0 for the non nonresponder at each visit.
Week 1 was considered as the Baseline.
The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing as well.
Change from Baseline of Week 16 and Week 24 are incorporated here which are Follow up weeks.
|
Week 16 and 24
|
Percentage of Participants Who Demonstrated a Clinically Meaningful Increase in FEV1 Over the 12 Week Assessment Period
Time Frame: Upto 12 weeks
|
FEV1 is forced expiratory volume in 1 second.A participant is defined as a FEV1 responder if he/she achieves a change from baseline FEV1 of >=200ml.
To evaluate whether the participant was a responder over 12 weeks, change from baseline FEV1 over 12 weeks was calculated by taking the mean of the changes at Visit 7, Visit 9 and Visit 11.
A binary variable was created for each participant with 1 for the responder and 0 for the non-responder.
If either Visit 9 or Visit 11 FEV1 data are missing, then the binary variable for the responder over 12 weeks was set to be missing.
If Visit 7 data were missing, but Visit 9 and Visit 11 data were available, then the binary variable for the responder over 12 weeks was still calculated.
|
Upto 12 weeks
|
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Week 25
|
An AE is any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
|
Up to Week 25
|
Number of Participants With Abnormal Vital Signs of Potential Clinical Importance: Systolic and Distolic Blood Pressure and Heart Rate.
Time Frame: Screening, Day -28, 1, 15, 29, 50, 57 and 169 (follow-up 3)
|
Vital signs including systolic and diastolic blood pressure and heart rate taken at certain visits from screening to follow-up.
Potential Clinical Importance Ranges were systolic blood pressure (<85 and >160millimeter of mercury [mmHg]), diastolic blood pressure (<45 and >100 mmHg) and heart rate (<40 and >110 beats per minute [BPM]).
Number of participants with abnormal systolic blood pressure, diastolic blood pressure and heart rate values of potential clinical importance were summarized.
|
Screening, Day -28, 1, 15, 29, 50, 57 and 169 (follow-up 3)
|
Number of Participants With Clinically Significant Abnormality in 12-lead Electrocardiogram (ECG)
Time Frame: Upto Week 25
|
Single 12-lead ECGs were obtained at certain visits from screening to follow-up.
ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and Corrected QT (QTc) intervals.
Number of participants with clinically significant abnormality in 12-lead ECG readings were summarized.
|
Upto Week 25
|
Number of Participants With Abnormal Hematological Parameters of Potential Clinical Importance
Time Frame: Upto Week 25
|
Blood samples were collected on each visit from Week 1 to Week 25 to assess the haematological parameters.
White Blood Cells count, Neutrophils, Haemoglobin, Hematocrit, Count and Lymphocytes were analyzed in haematology.
Number of participants with any abnormal hematological parameters of potential clinical importance are summarized here.
|
Upto Week 25
|
Number of Participants With Abnormal Clinical Chemistry Parameters of Potential Clinical Importance
Time Frame: Upto Week 25
|
Blood samples were collected on each visit from Week 1 to Week 25 to assess the clinical chemistry parameters.
Albumin, Calcium, Glucose, Pottasium, Sodium and Total Carbon Di-oxide were analyzed in clinical chemistry.
Number of participants with any abnormal clinical chemistry parameters of potential clinical importance are summarized here.
|
Upto Week 25
|
Number of Participants With Abnormal Urinanalysis Parameters of Potential Clinical Importance
Time Frame: Upto Week 25
|
Samples were collected on each visit from Week 1 to Week 25 for urinalysis.
Number of participants with any abnormal urinalysis parameters of potential clinical importance are summarized here.
|
Upto Week 25
|
Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over the Dosing Interval (AUC (0-τ)).
Time Frame: Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
Plasma concentration-time data were well described by a 2-compartment model with first order elimination.
Plasma concentrations of GSK679586 were determined at Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
However, the derived PK parameters were determined only for the day of infusion administration.
i.e.
Day 1, Day 29 and Day 57.
The AUC at Day 1 indicates AUC(0-1 h), Day 29 indicated AUC(0-672 h) and Day 57 indicated AUC(0-1344h).
AUC(0-τ) for each participant was reconstructed from sparse PK sampling using Bayesian prediction obtained from a population PK model using nonlinear mixed effects methods (NONMEM, version V).
|
Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
PK Parameter:Maximum Observed Concentration (Cmax)
Time Frame: Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
Plasma concentration-time data were well described by a 2-compartment model with first order elimination.
Plasma concentrations of GSK679586 were determined at Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
However, Cmax were determined only for the day of infusion administration.
i.e.
Day 1, Day 29 and Day 57.
The Cmax at Day 1 indicates Cmax(0-1 h), Day 29 indicated Cmax(0-672 h) and Day 57 indicated Cmax(0-1344 h).
Cmax for each participant was reconstructed from sparse PK sampling using Bayesian prediction obtained from a population PK model using nonlinear mixed effects methods (NONMEM, version V).
|
Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
PK Parameter: Systemic Clearance of Parent Drug
Time Frame: Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
Plasma concentration-time data were well described by a 2-compartment model with first order elimination.
Plasma concentrations of GSK679586 were determined at Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
However, systemic clearance were determined only for the day of infusion administration.
i.e.
Day 1, Day 29 and Day 57.
The systemic clearance at Day 1 indicates systemic clearance(0-1 h), Day 29 indicated systemic clearance(0-672 h) and Day 57 indicated systemic clearance(0-1344 h).
Systemic clearance of parent drug for each participant was reconstructed from sparse PK sampling using Bayesian prediction obtained from a population PK model using nonlinear mixed effects methods (NONMEM, version V).
|
Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
PK Parameter: Volume of Distribution
Time Frame: Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
Plasma concentration-time data were well described by a 2-compartment model with first order elimination.
Plasma concentrations of GSK679586 were determined at Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
However, volume of distribution were determined only for the day of infusion administration.
i.e.
Day 1, Day 29 and Day 57.
The volume of distribution at Day 1 indicates volume of distribution(0-1 h), Day 29 indicated volume of distribution (0-672 h) and Day 57 indicated volume of distribution (0-1344 h).
Volume of distribution for each participant was reconstructed from sparse PK sampling using Bayesian prediction obtained from a population PK model using nonlinear mixed effects methods (NONMEM, version V).
The 2-compartment model provided the data for volume of distribution of central compartment (V1) and volume distribution of peripheral compartment (V2).
|
Day 1 (Pre-dose, 0.25h, 1.00h), Day 4 (72h), Day 29 (672 h), Day 57 (1344h), Day 61 (1440h), Day 85 (2016h), Day 141 (3360h), Day 169 (4032h) and Follow up visits.
|
Number of Participants With Confirmed Positive Anti-GSK679586 Antibody Results After Initiation of Study Treatment
Time Frame: Up to Week 25
|
Serum samples were tested for presence of anti-GSK679586 antibodies.
Blood samples were collected via an indwelling cannula or by direct venepuncture collected into a serum separator tube and allowed to clot for 1 to 2 hours.
Samples were centrifuged and the resultant serum was transferred to 3 separate cryovials and stored at -80°C until shipped on dry ice to the central laboratory.
Samples were analyzed in a tiered assay format.
Number of participants with confirmed positive Anti-GSK679586 antibody results after initiation of study treatment were reported.
|
Up to Week 25
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2008
Primary Completion (Actual)
July 25, 2010
Study Completion (Actual)
July 25, 2010
Study Registration Dates
First Submitted
February 5, 2009
First Submitted That Met QC Criteria
February 12, 2009
First Posted (Estimate)
February 13, 2009
Study Record Updates
Last Update Posted (Actual)
December 12, 2017
Last Update Submitted That Met QC Criteria
November 13, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Fluticasone
- Xhance
Other Study ID Numbers
- 106870
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Study Protocol
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 106870Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on INTRAVENOUS GSK679586
-
GlaxoSmithKlineCompleted
-
Royan InstituteCompletedChronic Kidney DiseaseIran, Islamic Republic of
-
University of MinnesotaCompleted
-
Galapagos NVMorphoSys AGCompletedHealthy | Dermatitis, AtopicBelgium, Hungary, Moldova, Republic of, Romania
-
MicuRxWorldwide Clinical TrialsCompleted
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
Eli Lilly and CompanyCompleted
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP6294United Kingdom
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular DystrophyIndia
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedAmyotrophic Lateral SclerosisSpain